

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1. (Previously Presented) A process for producing a fenofibrate composition comprising:
  - (i) preparing a suspension comprising at least one hydrophilic polymer, and micronized fenofibrate;
  - (ii) spraying the suspension onto inert carriers.
2. (Previously Presented) The process of claim 1, wherein step (i) of preparing the suspension comprises (a) preparing a solution comprising at least one hydrophilic polymer and (b) adding the micronized fenofibrate to said solution to produce the suspension.
3. (Previously Presented) The process of claim 1, wherein step (i) of preparing the suspension comprises (a) preparing a solution comprising at least one hydrophilic polymer by dissolving said hydrophilic polymer and (b) adding the micronized fenofibrate to said solution to produce the suspension.
4. (Previously Presented) The process of claim 1, wherein step (i) of preparing the suspension comprises (a) adding the micronized fenofibrate to a solution to form the suspension, and (b) dissolving at least one hydrophilic polymer in the suspension.
5. (Previously Presented) The process of claim 1, wherein the suspension is an aqueous suspension.
6. (Previously Presented) The process of claim 1, wherein the suspension further comprises at least one surfactant.
7. (Previously Presented) The process of claim 1, wherein said suspension comprises fenofibrate and hydrophilic polymer in a weight ratio of fenofibrate/hydrophilic polymer between 1/10 and 4/1.

8. (Previously Presented) The process of claim 1, wherein said suspension comprises fenofibrate and hydrophilic polymer in a weight ratio of fenofibrate/hydrophilic polymer between 1/2 and 2/1.

9. (Previously Presented) The process of claim 1, wherein the fenofibrate has a particle size less than 20  $\mu\text{m}$ .

10. (Previously Presented) The process of claim 1, wherein the fenofibrate has a particle size less than 10  $\mu\text{m}$ .

11. (Previously Presented) The process of claim 1, wherein said suspension comprises fenofibrate in an amount from 1 to 40% by weight.

12. (Previously Presented) The process of claim 1, wherein said suspension comprises fenofibrate in an amount from 10 to 25% by weight.

13. (Previously Presented) The process of claim 1, wherein said suspension comprises the hydrophilic polymer in an amount from 5 to 40% by weight.

14. (Previously Presented) The process of claim 1, wherein said suspension comprises the hydrophilic polymer in an amount from 10 to 25% by weight.

15. (Previously Presented) The process of claim 1, wherein the hydrophilic polymer is a polyvinylpyrrolidone, a poly(vinyl alcohol), a hydroxypropylcellulose, a hydroxy-methylcellulose, a hydroxypropylmethylcellulose, a gelatin, or a mixture of two or more thereof.

16. (Previously Presented) The process of claim 1, wherein the hydrophilic polymer is a polyvinylpyrrolidone.

17. (Previously Presented) The process of claim 6, wherein said suspension comprises the surfactant in an amount of up to 10% by weight.

18. (Previously Presented) The process of claim 6, wherein said suspension comprises the surfactant in an amount of up to 5% by weight.

19. (Previously Presented) The process of claim 6, wherein said suspension comprises surfactant and hydrophilic polymer in a weight ratio of surfactant/hydrophilic polymer between 1/500 and 1/10.

20. (Previously Presented) The process of claim 6, wherein said suspension comprises surfactant and hydrophilic polymer in a weight ratio of surfactant/hydrophilic polymer between 1/100 and 5/100.

21. (Previously Presented) The process of claim 6, wherein the surfactant is sodium lauryl sulfate, monooleate, monolaurate, monopalmitate, monostearate or another ester of polyoxyethylene sorbitane, sodium dioctylsulfosuccinate, lecithin, stearyl alcohol, cetostearyl alcohol, cholesterol, polyoxyethylene ricin oil, polyoxyethylene fatty acid glycerides, poloxamer, or a mixture of two or more thereof.

22. (Previously Presented) The process of claim 6, wherein the surfactant is sodium lauryl sulfate.

23. (Previously Presented) The process of claim 1, wherein the inert carriers are inert hydrosoluble carriers.

24. (Previously Presented) The process of claim 1, wherein step (ii) comprises spraying the suspension onto inert carriers to form granulates.

25. (Previously Presented) The process of claim 24, further comprising step (iii) comprising compressing the granulates to form the fenofibrate tablet.

26. (Previously Presented) The process of claim 25, which further comprises, between steps (ii) and (iii), mixing the granulates with at least one pharmaceutical excipient.

27. (Previously Presented) The process of claim 26, wherein said pharmaceutical excipient is selected from the group consisting of at least one binder, at least one filler, at least one pigment, at least one disintegrating agent, at least one lubricant, at least one wetting agent, at least one buffer, and a mixture of two or more thereof.

28. (Previously Presented) The process of claim 26, wherein said pharmaceutical excipient is selected from the group consisting of microcrystalline cellulose, lactose, starch, colloidal silica, talc, glycerol esters, sodium stearyl fumarate, titanium dioxide, magnesium stearate, stearic acid, cross-linked polyvinyl pyrrolidone, carboxymethyl starch, hydroxypropylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, gelatin, and a mixture of two or more thereof.

29. (Previously Presented) A process for producing a fenofibrate tablet comprising:

- (i) preparing a suspension comprising at least one hydrophilic polymer, and micronized fenofibrate;
- (ii) spraying the suspension onto inert carriers to form granulates; and
- (iii) compressing the granulates to form the fenofibrate tablet.

30. (Previously Presented) The process of claim 29, wherein step (i) of preparing the suspension comprises (a) preparing a solution comprising at least one hydrophilic polymer and (b) adding the micronized fenofibrate to said solution to produce the suspension.

31. (Previously Presented) The process of claim 29, wherein step (i) of preparing the suspension comprises (a) preparing a solution comprising at least one hydrophilic polymer by dissolving said hydrophilic polymer and (b) adding the micronized fenofibrate to said solution to produce the suspension.

32. (Previously Presented) The process of claim 29, wherein step (i) of preparing the suspension comprises (a) adding the micronized fenofibrate to a solution to form the suspension, and (b) dissolving at least one hydrophilic polymer in the suspension.

33. (Previously Presented) The process of claim 29, wherein the suspension is an aqueous suspension.

34. (Previously Presented) The process of claim 29, wherein the suspension further comprises at least one surfactant.

35. (Previously Presented) The process of claim 29, wherein said suspension comprises fenofibrate and hydrophilic polymer in a weight ratio of fenofibrate/hydrophilic polymer between 1/10 and 4/1.

36. (Previously Presented) The process of claim 29, wherein said suspension comprises fenofibrate and hydrophilic polymer in a weight ratio of fenofibrate/hydrophilic polymer between 1/2 and 2/1.

37. (Previously Presented) The process of claim 29, wherein the fenofibrate has a particle size less than 20  $\mu\text{m}$ .

38. (Previously Presented) The process of claim 29, wherein the fenofibrate has a particle size less than 10  $\mu\text{m}$ .

39. (Previously Presented) The process of claim 29, wherein said suspension comprises fenofibrate in an amount from 1 to 40% by weight.

40. (Previously Presented) The process of claim 29, wherein said suspension comprises fenofibrate in an amount from 10 to 25% by weight.

41. (Previously Presented) The process of claim 29, wherein said suspension comprises the hydrophilic polymer in an amount from 5 to 40% by weight.

42. (Previously Presented) The process of claim 29, wherein said suspension comprises the hydrophilic polymer in an amount from 10 to 25% by weight.

43. (Previously Presented) The process of claim 29, wherein the hydrophilic polymer is a polyvinylpyrrolidone, a poly(vinyl alcohol), a hydroxypropylcellulose, a hydroxy-methylcellulose, a hydroxypropylmethylcellulose, a gelatin, or a mixture of two or more thereof.

44. (Previously Presented) The process of claim 29, wherein the hydrophilic polymer is a polyvinylpyrrolidone.

45. (Previously Presented) The process of claim 34, wherein said suspension comprises the surfactant in an amount of up to 10% by weight.

46. (Previously Presented) The process of claim 34, wherein said suspension comprises the surfactant in an amount of up to 5% by weight.

47. (Previously Presented) The process of claim 34, wherein said suspension comprises surfactant and hydrophilic polymer in a weight ratio of surfactant/hydrophilic polymer between 1/500 and 1/10.

48. (Previously Presented) The process of claim 34, wherein said suspension comprises surfactant and hydrophilic polymer in a weight ratio of surfactant/hydrophilic polymer between 1/100 and 5/100.

49. (Previously Presented) The process of claim 34, wherein the surfactant is sodium lauryl sulfate, monooleate, monolaurate, monopalmitate, monostearate or another ester of polyoxyethylene sorbitane, sodium dioctylsulfosuccinate, lecithin, stearic

alcohol, cetostearyl alcohol, cholesterol, polyoxyethylene ricin oil, polyoxyethylene fatty acid glycerides, poloxamer, or a mixture of two or more thereof.

50. (Previously Presented) The process of claim 34, wherein the surfactant is sodium lauryl sulfate.

51. (Previously Presented) The process of claim 29, wherein the inert carriers are inert hydrosoluble carriers.

52. (Previously Presented) The process of claim 29, which further comprises, between steps (ii) and (iii), mixing the granulates with at least one pharmaceutical excipient.

53. (Previously Presented) The process of claim 52, wherein said pharmaceutical excipient is selected from the group consisting of at least one binder, at least one filler, at least one pigment, at least one disintegrating agent, at least one lubricant, at least one wetting agent, at least one buffer, and a mixture of two or more thereof.

54. (Previously Presented) The process of claim 52, wherein said pharmaceutical excipient is selected from the group consisting of microcrystalline cellulose, lactose, starch, colloidal silica, talc, glycerol esters, sodium stearyl fumarate, titanium dioxide, magnesium stearate, stearic acid, cross-linked polyvinyl pyrrolidone, carboxymethyl starch, hydroxypropylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, gelatin, and a mixture of two or more thereof.

55. (Previously Presented) A process for producing a fenofibrate composition comprising:

- (i) preparing an aqueous suspension comprising at least one hydrophilic polymer, at least one surfactant, and micronized fenofibrate;
- (ii) spraying the aqueous suspension onto inert carriers.

56. (Previously Presented) The process of claim 55, wherein step (i) of preparing the aqueous suspension comprises (a) preparing an aqueous solution comprising at least one surfactant and at least one hydrophilic polymer and (b) adding the micronized fenofibrate to said aqueous solution to produce the aqueous suspension.

57. (Previously Presented) The process of claim 55, wherein step (i) of preparing the aqueous suspension comprises (a) preparing an aqueous solution comprising at least one surfactant and at least one hydrophilic polymer by dissolving said surfactant and hydrophilic polymer and (b) adding the micronized fenofibrate to said aqueous solution to produce the aqueous suspension.

58. (Previously Presented) The process of claim 55, wherein step (i) of preparing the aqueous suspension comprises (a) dissolving at least one surfactant in an aqueous solution, (b) dissolving at least one hydrophilic polymer in the aqueous solution, and (c) adding the micronized fenofibrate to said aqueous solution to produce the aqueous suspension.

59. (Previously Presented) The process of claim 55, wherein step (i) of preparing the aqueous suspension comprises (a) dissolving at least one hydrophilic polymer in an aqueous solution, (b) dissolving at least one surfactant in the aqueous solution, and (c) adding the micronized fenofibrate to said aqueous solution to form the aqueous suspension.

60. (Previously Presented) The process of claim 55, wherein step (i) of preparing the aqueous suspension comprises (a) dissolving at least one surfactant in an aqueous solution, (b) adding the micronized fenofibrate to said aqueous solution to form the aqueous suspension, and (c) dissolving at least one hydrophilic polymer in the aqueous suspension.

61. (Previously Presented) The process of claim 55, wherein step (i) of preparing the aqueous suspension comprises (a) dissolving at least one hydrophilic polymer in an aqueous solution, (b) adding the micronized fenofibrate to said aqueous solution to form the aqueous suspension, and (c) dissolving at least one surfactant in the aqueous suspension.

62. (Previously Presented) The process of claim 55, wherein step (i) of preparing the aqueous suspension comprises (a) adding the micronized fenofibrate to an aqueous solution to form the aqueous suspension, (b) dissolving at least one surfactant in the aqueous suspension, and (c) dissolving at least one hydrophilic polymer in the aqueous suspension.

63. (Previously Presented) The process of claim 55, wherein step (i) of preparing the aqueous suspension comprises (a) adding the micronized fenofibrate to an aqueous solution to form the aqueous suspension, (b) dissolving at least one hydrophilic polymer in the aqueous suspension, and (c) dissolving at least one surfactant in the aqueous suspension.

64. (Previously Presented) The process of claim 55, wherein said suspension comprises fenofibrate and hydrophilic polymer in a weight ratio of fenofibrate/hydrophilic polymer between 1/10 and 4/1.

65. (Previously Presented) The process of claim 55, wherein said suspension comprises fenofibrate and hydrophilic polymer in a weight ratio of fenofibrate/hydrophilic polymer between 1/2 and 2/1.

66. (Previously Presented) The process of claim 55, wherein the fenofibrate has a particle size less than 20  $\mu\text{m}$ .

67. (Previously Presented) The process of claim 55, wherein the fenofibrate has a particle size less than 10  $\mu\text{m}$ .

68. (Previously Presented) The process of claim 55, wherein said suspension comprises fenofibrate in an amount from 1 to 40% by weight.

69. (Previously Presented) The process of claim 55, wherein said suspension comprises fenofibrate in an amount from 10 to 25% by weight.

70. (Previously Presented) The process of claim 55, wherein said suspension comprises the hydrophilic polymer in an amount from 5 to 40% by weight.

71. (Previously Presented) The process of claim 55, wherein said suspension comprises the hydrophilic polymer in an amount from 10 to 25% by weight.

72. (Previously Presented) The process of claim 55, wherein the hydrophilic polymer is a polyvinylpyrrolidone, a poly(vinyl alcohol), a hydroxypropylcellulose, a hydroxy-methylcellulose, a hydroxypropylmethylcellulose, a gelatin, or a mixture of two or more thereof.

73. (Previously Presented) The process of claim 55, wherein the hydrophilic polymer is a polyvinylpyrrolidone.

74. (Previously Presented) The process of claim 55 wherein said suspension comprises the surfactant in an amount of up to 10% by weight.

75. (Previously Presented) The process of claim 55, wherein said suspension comprises the surfactant in an amount of up to 5% by weight.

76. (Previously Presented) The process of claim 55, wherein said suspension comprises surfactant and hydrophilic polymer in a weight ratio of surfactant/hydrophilic polymer between 1/500 and 1/10.

77. (Previously Presented) The process of claim 55, wherein said suspension comprises surfactant and hydrophilic polymer in a weight ratio of surfactant/hydrophilic polymer between 1/100 and 5/100.

78. (Previously Presented) The process of claim 55, wherein the surfactant is sodium lauryl sulfate, monooleate, monolaurate, monopalmitate, monostearate or another ester of polyoxyethylene sorbitane, sodium dioctylsulfosuccinate, lecithin, stearyl alcohol, cetostearyl alcohol, cholesterol, polyoxyethylene ricin oil, polyoxyethylene fatty acid glycerides, poloxamer, or a mixture of two or more thereof.

79. (Previously Presented) The process of claim 55, wherein the surfactant is sodium lauryl sulfate.

80. (Previously Presented) The process of claim 55, wherein the inert carriers are inert hydrosoluble carriers.

81. (Previously Presented) The process of claim 55, wherein step (ii) comprises spraying the suspension onto inert carriers to form granulates.

82. (Previously Presented) The process of claim 55, further comprising step (iii) comprising compressing the granulates to form the fenofibrate tablet.

83. (Previously Presented) The process of claim 82, which further comprises, between steps (ii) and (iii), mixing the granulates with at least one pharmaceutical excipient.

84. (Previously Presented) The process of claim 83, wherein said pharmaceutical excipient is selected from the group consisting of at least one binder, at least one filler, at least one pigment, at least one disintegrating agent, at least one

lubricant, at least one wetting agent, at least one buffer, and a mixture of two or more thereof.

85. (Previously Presented) The process of claim 83, wherein said pharmaceutical excipient is selected from the group consisting of microcrystalline cellulose, lactose, starch, colloidal silica, talc, glycerol esters, sodium stearyl fumarate, titanium dioxide, magnesium stearate, stearic acid, cross-linked polyvinyl pyrrolidone, carboxymethyl starch, hydroxypropylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, gelatin, and a mixture of two or more thereof.

86. (Previously Presented) A process for producing a fenofibrate tablet comprising:

- (i) preparing an aqueous suspension comprising at least one surfactant, at least one hydrophilic polymer, and micronized fenofibrate;
- (ii) spraying the aqueous suspension onto inert carriers to form granulates; and
- (iii) compressing the granulates to form the fenofibrate tablet.

87. (Previously Presented) The process of claim 86, wherein step (i) of preparing the aqueous suspension comprises (a) preparing an aqueous solution comprising at least one surfactant and at least one hydrophilic polymer and (b) adding the micronized fenofibrate to said aqueous solution to produce the aqueous suspension.

88. (Previously Presented) The process of claim 86, wherein step (i) of preparing the aqueous suspension comprises (a) preparing an aqueous solution comprising at least one surfactant and at least one hydrophilic polymer by dissolving said surfactant and hydrophilic polymer and (b) adding the micronized fenofibrate to said aqueous solution to produce the aqueous suspension.

89. (Previously Presented) The process of claim 86, wherein step (i) of preparing the aqueous suspension comprises (a) dissolving at least one surfactant in an aqueous solution, (b) dissolving at least one hydrophilic polymer in the aqueous solution, and (c) adding the micronized fenofibrate to said aqueous solution to produce the aqueous suspension.

90. (Previously Presented) The process of claim 86, wherein step (i) of preparing the aqueous suspension comprises (a) dissolving at least one hydrophilic

polymer in an aqueous solution, (b) dissolving at least one surfactant in the aqueous solution, and (c) adding the micronized fenofibrate to said aqueous solution to form the aqueous suspension.

91. (Previously Presented) The process of claim 86, wherein step (i) of preparing the aqueous suspension comprises (a) dissolving at least one surfactant in an aqueous solution, (b) adding the micronized fenofibrate to said aqueous solution to form the aqueous suspension, and (c) dissolving at least one hydrophilic polymer in the aqueous suspension.

92. (Previously Presented) The process of claim 86, wherein step (i) of preparing the aqueous suspension comprises (a) dissolving at least one hydrophilic polymer in an aqueous solution, (b) adding the micronized fenofibrate to said aqueous solution to form the aqueous suspension, and (c) dissolving at least one surfactant in the aqueous suspension.

93. (Previously Presented) The process of claim 86, wherein said suspension comprises fenofibrate and hydrophilic polymer in a weight ratio of fenofibrate/hydrophilic polymer between 1/10 and 4/1.

94. (Previously Presented) The process of claim 86, wherein said suspension comprises fenofibrate and hydrophilic polymer in a weight ratio of fenofibrate/hydrophilic polymer between 1/2 and 2/1.

95. (Previously Presented) The process of claim 86, wherein the fenofibrate has a particle size less than 20  $\mu\text{m}$ .

96. (Previously Presented) The process of claim 86, wherein the fenofibrate has a particle size less than 10  $\mu\text{m}$ .

97. (Previously Presented) The process of claim 86, wherein said suspension comprises fenofibrate in an amount from 1 to 40% by weight.

98. (Previously Presented) The process of claim 86, wherein said suspension comprises fenofibrate in an amount from 10 to 25% by weight.

99. (Previously Presented) The process of claim 86, wherein said suspension comprises the hydrophilic polymer in an amount from 5 to 40% by weight.

100. (Previously Presented) The process of claim 86, wherein said suspension comprises the hydrophilic polymer in an amount from 10 to 25% by weight.

101. (Previously Presented) The process of claim 86, wherein the hydrophilic polymer is a polyvinylpyrrolidone, a poly(vinyl alcohol), a hydroxypropylcellulose, a hydroxy-methylcellulose, a hydroxypropylmethylcellulose, a gelatin, or a mixture of two or more thereof.

102. (Previously Presented) The process of claim 86, wherein the hydrophilic polymer is a polyvinylpyrrolidone.

103. (Previously Presented) The process of claim 86, wherein said suspension comprises the surfactant in an amount of up to 10% by weight.

104. (Previously Presented) The process of claim 86, wherein said suspension comprises the surfactant in an amount of up to 5% by weight.

105. (Previously Presented) The process of claim 86, wherein said suspension comprises surfactant and hydrophilic polymer in a weight ratio of surfactant/hydrophilic polymer between 1/500 and 1/10.

106. (Previously Presented) The process of claim 86, wherein said suspension comprises surfactant and hydrophilic polymer in a weight ratio of surfactant/hydrophilic polymer between 1/100 and 5/100.

107. (Previously Presented) The process of claim 86, wherein the surfactant is sodium lauryl sulfate, monooleate, monolaurate, monopalmitate, monostearate or another ester of polyoxyethylene sorbitane, sodium dioctylsulfosuccinate, lecithin, stearyl alcohol, cetostearyl alcohol, cholesterol, polyoxyethylene ricin oil, polyoxyethylene fatty acid glycerides, poloxamer, or a mixture of two or more thereof.

108. (Previously Presented) The process of claim 86, wherein the surfactant is sodium lauryl sulfate.

109. (Previously Presented) The process of claim 86, wherein the inert carriers are inert hydrosoluble carriers.

110. (Previously Presented) The process of claim 86, which further comprises, between steps (ii) and (iii), mixing the granulates with at least one pharmaceutical excipient.

111. (Previously Presented) The process of claim 110, wherein said pharmaceutical excipient is selected from the group consisting of at least one binder, at least one filler, at least one pigment, at least one disintegrating agent, at least one lubricant, at least one wetting agent, at least one buffer, and a mixture of two or more thereof.

112. (Previously Presented) The process of claim 110, wherein said pharmaceutical excipient is selected from the group consisting of microcrystalline cellulose, lactose, starch, colloidal silica, talc, glycerol esters, sodium stearyl fumarate, titanium dioxide, magnesium stearate, stearic acid, cross-linked polyvinyl pyrrolidone, carboxymethyl starch, hydroxypropylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, gelatin, and a mixture of two or more thereof.

113. (Previously Presented) A process for producing a fenofibrate composition comprising:

- (i) preparing an aqueous suspension comprising polyvinylpyrrolidone, sodium lauryl sulfate, and micronized fenofibrate;
- (ii) spraying the aqueous suspension onto inert carriers.

114. (Previously Presented) The process of claim 113, wherein step (i) of preparing the aqueous suspension comprises (a) preparing an aqueous solution comprising polyvinylpyrrolidone and sodium lauryl sulfate and (b) adding the micronized fenofibrate to said aqueous solution to produce the aqueous suspension.

115. (Previously Presented) The process of claim 113, wherein step (i) of preparing the aqueous suspension comprises (a) preparing an aqueous solution comprising polyvinylpyrrolidone and sodium lauryl sulfate by dissolving said polyvinylpyrrolidone and sodium lauryl sulfate and (b) adding the micronized fenofibrate to said aqueous solution to produce the aqueous suspension.

116. (Previously Presented) The process of claim 113, wherein said suspension comprises fenofibrate and polyvinylpyrrolidone in a weight ratio of fenofibrate/polyvinylpyrrolidone between 1/10 and 4/1.

117. (Previously Presented) The process of claim 113, wherein said suspension comprises fenofibrate and polyvinylpyrrolidone in a weight ratio of fenofibrate/polyvinylpyrrolidone between 1/2 and 2/1.

118. (Previously Presented) The process of claim 113, wherein the fenofibrate has a particle size less than 20  $\mu\text{m}$ .

119. (Previously Presented) The process of claim 113, wherein the fenofibrate has a particle size less than 10  $\mu\text{m}$ .

120. (Previously Presented) The process of claim 113, wherein said suspension comprises fenofibrate in an amount from 1 to 40% by weight.

121. (Previously Presented) The process of claim 113, wherein said suspension comprises fenofibrate in an amount from 10 to 25% by weight.

122. (Previously Presented) The process of claim 113, wherein said suspension comprises polyvinylpyrrolidone in an amount from 5 to 40% by weight.

123. (Previously Presented) The process of claim 113, wherein said suspension comprises polyvinylpyrrolidone in an amount from 10 to 25% by weight.

124. (Previously Presented) The process of claim 113 wherein said suspension comprises sodium lauryl sulfate in an amount of up to 10% by weight.

125. (Previously Presented) The process of claim 113, wherein said suspension comprises sodium lauryl sulfate in an amount of up to 5% by weight.

126. (Previously Presented) The process of claim 113, wherein said suspension comprises sodium lauryl sulfate and polyvinylpyrrolidone in a weight ratio of sodium lauryl sulfate to polyvinylpyrrolidone between 1/500 and 1/10.

127. (Previously Presented) The process of claim 113, wherein said suspension comprises sodium lauryl sulfate and polyvinylpyrrolidone in a weight ratio of sodium lauryl sulfate to polyvinylpyrrolidone between 1/100 and 5/100.

128. (Previously Presented) The process of claim 113, wherein the inert carriers are inert hydrosoluble carriers.

129. (Previously Presented) The process of claim 113, wherein step (ii) comprises spraying the suspension onto inert carriers to form granulates.

130. (Previously Presented) A process for producing a fenofibrate tablet comprising:

- (i) preparing an aqueous suspension comprising at least one surfactant, at least one hydrophilic polymer, and micronized fenofibrate; by (a) preparing an aqueous solution comprising at least one surfactant and at least one hydrophilic polymer by dissolving said surfactant and hydrophilic polymer and (b) adding the micronized fenofibrate to said solution to produce the aqueous suspension;
- (ii) spraying the aqueous suspension onto inert carriers to form granulates; and
- (iii) compressing the granulates to form the fenofibrate tablet.

131. (Previously Presented) The process of claim 130, wherein said suspension comprises fenofibrate and hydrophilic polymer in a weight ratio of fenofibrate/hydrophilic polymer between 1/10 and 4/1.

132. (Previously Presented) The process of claim 130, wherein said suspension comprises fenofibrate and hydrophilic polymer in a weight ratio of fenofibrate/hydrophilic polymer between 1/2 and 2/1.

133. (Previously Presented) The process of claim 130, wherein the fenofibrate has a particle size less than 20  $\mu\text{m}$ .

134. (Previously Presented) The process of claim 130, wherein the fenofibrate has a particle size less than 10  $\mu\text{m}$ .

135. (Previously Presented) The process of claim 130, wherein said suspension comprises fenofibrate in an amount from 1 to 40% by weight.

136. (Previously Presented) The process of claim 130, wherein said suspension comprises fenofibrate in an amount from 10 to 25% by weight.

137. (Previously Presented) The process of claim 130, wherein said suspension comprises the hydrophilic polymer in an amount from 5 to 40% by weight.

138. (Previously Presented) The process of claim 130, wherein said suspension comprises the hydrophilic polymer in an amount from 10 to 25% by weight.

139. (Previously Presented) The process of claim 130, wherein the hydrophilic polymer is a polyvinylpyrrolidone, a poly(vinyl alcohol), a hydroxypropylcellulose, a

hydroxy-methylcellulose, a hydroxypropylmethylcellulose, a gelatin, or a mixture of two or more thereof.

140. (Previously Presented) The process of claim 130, wherein the hydrophilic polymer is a polyvinylpyrrolidone.

141. (Previously Presented) The process of claim 130, wherein said suspension comprises the surfactant in an amount of up to 10% by weight.

142. (Previously Presented) The process of claim 130, wherein said suspension comprises the surfactant in an amount of up to 5% by weight.

143. (Previously Presented) The process of claim 130, wherein said suspension comprises surfactant and hydrophilic polymer in a weight ratio of surfactant/hydrophilic polymer between 1/500 and 1/10.

144. (Previously Presented) The process of claim 130, wherein said suspension comprises surfactant and hydrophilic polymer in a weight ratio of surfactant/hydrophilic polymer between 1/100 and 5/100.

145. (Previously Presented) The process of claim 130, wherein the surfactant is sodium lauryl sulfate, monooleate, monolaurate, monopalmitate, monostearate or another ester of polyoxyethylene sorbitane, sodium dioctylsulfosuccinate, lecithin, stearyl alcohol, cetostearyl alcohol, cholesterol, polyoxyethylene ricin oil, polyoxyethylene fatty acid glycerides, poloxamer, or a mixture of two or more thereof.

146. (Previously Presented) The process of claim 130, wherein the surfactant is sodium lauryl sulfate.

147. (Previously Presented) The process of claim 130, wherein the inert carriers are inert hydrosoluble carriers.

148. (Previously Presented) The process of claim 130, which further comprises, between steps (ii) and (iii), mixing the granulates with at least one pharmaceutical excipient.

149. (Previously Presented) The process of claim 148, wherein said pharmaceutical excipient is selected from the group consisting of at least one binder, at least one filler, at least one pigment, at least one disintegrating agent, at least one

lubricant, at least one wetting agent, at least one buffer, and a mixture of two or more thereof.

150. (Previously Presented) The process of claim 148, wherein said pharmaceutical excipient is selected from the group consisting of microcrystalline cellulose, lactose, starch, colloidal silica, talc, glycerol esters, sodium stearyl fumarate, titanium dioxide, magnesium stearate, stearic acid, cross-linked polyvinyl pyrrolidone, carboxymethyl starch, hydroxypropylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, gelatin, and a mixture of two or more thereof.

151. (Previously Presented) A process for producing a fenofibrate tablet comprising:

- (i) preparing an aqueous suspension comprising sodium lauryl sulfate, polyvinylpyrrolidone, and micronized fenofibrate; and wherein the weight ratio of fenofibrate/polyvinylpyrrolidone is between 1/10 and 4/1 and the weight ratio of sodium lauryl sulfate/polyvinylpyrrolidone being between 1/500 and 1/10;
- (ii) spraying the aqueous suspension onto inert carriers to form granulates; and
- (iii) compressing the granulates to form the fenofibrate tablet.

152. (Previously Presented) The process of claim 151, wherein step (i) of preparing the aqueous suspension comprises (a) preparing an aqueous solution comprising sodium lauryl sulfate, polyvinylpyrrolidone and (b) adding the micronized fenofibrate to said aqueous solution to produce the aqueous suspension.

153. (Previously Presented) The process of claim 151, wherein step (i) of preparing the aqueous suspension comprises (a) preparing an aqueous solution comprising sodium lauryl sulfate, polyvinylpyrrolidone by dissolving sodium lauryl sulfate, polyvinylpyrrolidone and (b) adding the micronized fenofibrate to said aqueous solution to produce the aqueous suspension.

154. (Previously Presented) The process of claim 151, wherein said suspension comprises fenofibrate and polyvinylpyrrolidone in a weight ratio of fenofibrate/polyvinylpyrrolidone between 1/2 and 2/1.

155. (Previously Presented) The process of claim 151, wherein the fenofibrate has a particle size less than 20  $\mu\text{m}$ .

156. (Previously Presented) The process of claim 151, wherein the fenofibrate has a particle size less than 10  $\mu\text{m}$ .

157. (Previously Presented) The process of claim 151, wherein said suspension comprises fenofibrate in an amount from 1 to 40% by weight.

158. (Previously Presented) The process of claim 151, wherein said suspension comprises fenofibrate in an amount from 10 to 25% by weight.

159. (Previously Presented) The process of claim 151, wherein said suspension comprises polyvinylpyrrolidone in an amount from 5 to 40% by weight.

160. (Previously Presented) The process of claim 151, wherein said suspension comprises polyvinylpyrrolidone in an amount from 10 to 25% by weight.

161. (Previously Presented) The process of claim 151, wherein said suspension comprises sodium lauryl sulfate in an amount of up to 10% by weight.

162. (Previously Presented) The process of claim 151, wherein said suspension comprises sodium lauryl sulfate in an amount of up to 5% by weight.

163. (Previously Presented) The process of claim 151, wherein said suspension comprises sodium lauryl sulfate and polyvinylpyrrolidone in a weight ratio of sodium lauryl sulfate to polyvinylpyrrolidone between 1/100 and 5/100.

164. (Previously Presented) The process of claim 151, wherein the inert carriers are inert hydrosoluble carriers.

165. (Previously Presented) The process of claim 151, which further comprises, between steps (ii) and (iii), mixing the granulates with at least one pharmaceutical excipient.

166. (Previously Presented) The process of claim 165, wherein said pharmaceutical excipient is selected from the group consisting of at least one binder, at least one filler, at least one pigment, at least one disintegrating agent, at least one lubricant, at least one wetting agent, at least one buffer, and a mixture of two or more thereof.

167. (Previously Presented) The process of claim 165, wherein said pharmaceutical excipient is selected from the group consisting of microcrystalline cellulose, lactose, starch, colloidal silica, talc, glycerol esters, sodium stearyl fumarate,

titanium dioxide, magnesium stearate, stearic acid, cross-linked polyvinyl pyrrolidone, carboxymethyl starch, hydroxypropylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, gelatin, and a mixture of two or more thereof.

168-182. (Cancelled)

183. (Previously Presented) The process of claim 1, wherein the composition comprises from 5 to 50% by weight of fenofibrate, from 10 to 75% by weight of carrier, and from 20 to 60% by weight of hydrophilic polymer.

184. (Previously Presented) The process of claim 1, wherein the composition comprises from 20 to 45% by weight of fenofibrate, from 20 to 50% by weight of carrier, and from 25 to 45% by weight of hydrophilic polymer.

185. (Previously Presented) The process of claim 183, wherein the composition further comprises up to 10% by weight of surfactant.

186. (Previously Presented) The process of claim 184, wherein the composition further comprises from 0.1 to 3% by weight of surfactant.

187. (Previously Presented) The process of claim 29, wherein the tablet comprises from 5 to 50% by weight of fenofibrate, from 10 to 75% by weight of carrier, and from 20 to 60% by weight of hydrophilic polymer.

188. (Previously Presented) The process of claim 29, wherein the tablet comprises from 20 to 45% by weight of fenofibrate, from 20 to 50% by weight of carrier, and from 25 to 45% by weight of hydrophilic polymer.

189. (Previously Presented) The process of claim 187, wherein the tablet further comprises up to 10% by weight of surfactant.

190. (Previously Presented) The process of claim 188, wherein the tablet further comprises from 0.1 to 3% by weight of surfactant.

191. (Previously Presented) The process of claim 55, wherein the composition comprises from 5 to 50% by weight of fenofibrate, from 10 to 75% by weight of carrier, from 20 to 60% by weight of hydrophilic polymer, and up to 10% by weight of surfactant.

192. (Previously Presented) The process of claim 55, wherein the composition comprises from 20 to 45% by weight of fenofibrate, from 20 to 50% by weight of carrier,

from 25 to 45% by weight of hydrophilic polymer, and from 0.1 to 3% by weight of surfactant.

193. (Previously Presented) The process of claim 86, wherein the tablet comprises from 5 to 50% by weight of fenofibrate, from 10 to 75% by weight of carrier, from 20 to 60% by weight of hydrophilic polymer, and up to 10% by weight of surfactant.

194. (Previously Presented) The process of claim 86, wherein the tablet comprises from 20 to 45% by weight of fenofibrate, from 20 to 50% by weight of carrier, from 25 to 45% by weight of hydrophilic polymer, and from 0.1 to 3% by weight of surfactant.

195. (Previously Presented) The process of claim 113, wherein the composition comprises from 5 to 50% by weight of fenofibrate, from 10 to 75% by weight of carrier, from 20 to 60% by weight of polyvinylpyrrolidone, and up to 10% by weight of sodium lauryl sulfate.

196. (Previously Presented) The process of claim 113, wherein the composition comprises from 20 to 45% by weight of fenofibrate, from 20 to 50% by weight of carrier, from 25 to 45% by weight of polyvinylpyrrolidone, and from 0.1 to 3% by weight of sodium lauryl sulfate.

197. (Previously Presented) The process of claim 130, wherein the tablet comprises from 5 to 50% by weight of fenofibrate, from 10 to 75% by weight of carrier, from 20 to 60% by weight of hydrophilic polymer, and up to 10% by weight of surfactant.

198. (Previously Presented) The process of claim 130, wherein the tablet comprises from 20 to 45% by weight of fenofibrate, from 20 to 50% by weight of carrier, from 25 to 45% by weight of hydrophilic polymer, and from 0.1 to 3% by weight of surfactant.

199. (Previously Presented) The process of claim 151, wherein the tablet comprises from 5 to 50% by weight of fenofibrate, from 10 to 75% by weight of carrier, from 20 to 60% by weight of polyvinylpyrrolidone, and up to 10% by weight of sodium lauryl sulfate.

200. (Previously Presented) The process of claim 151, wherein the tablet comprises from 20 to 45% by weight of fenofibrate, from 20 to 50% by weight of carrier, from 25 to 45% by weight of polyvinylpyrrolidone, and from 0.1 to 3% by weight of sodium lauryl sulfate.

201-202. (Cancelled)

203. (New) The process of claim 1, wherein the fenofibrate composition is in the form of a tablet.

204. (New) The process of claim 1, wherein the fenofibrate composition is in the form of a capsule.

205. (New) The process of claim 1, wherein the fenofibrate composition is in the form of granules inside a capsule.

206. (New) The process of claim 1, wherein the fenofibrate composition is in the form of a granulate.

207. (New) The process of claim 55, wherein the fenofibrate composition is in the form of a tablet.

208. (New) The process of claim 55, wherein the fenofibrate composition is in the form of a capsule.

209. (New) The process of claim 55, wherein the fenofibrate composition is in the form of granules inside a capsule.

210. (New) The process of claim 55, wherein the fenofibrate composition is in the form of a granulate.